Immunovant financials
$33.46−0.09%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 | FY24 Mar 31 | FY23 Mar 31 | FY22 Mar 31 | FY21 Mar 31 | FY20 Mar 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$532.9M | -$438.2M | -$282.7M | -$218.3M | -$156.0M | -$108.1M | -$66.1M |
| Net income | -$505.6M | -$413.8M | -$259.3M | -$211.0M | -$156.7M | -$107.4M | -$66.4M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | $-1.54 |
| EBITDA | -$532.5M | -$437.8M | -$270.0M | -$218.1M | -$155.9M | -$108.1M | -$66.1M |
| Operating cash flow | -$407.3M | -$375.9M | -$214.2M | -$188.2M | -$106.1M | -$83.3M | -$53.4M |
| Free cash flow | -$407.3M | -$376.6M | -$214.6M | -$188.4M | -$106.4M | -$83.5M | -$53.4M |
| Diluted shares | 182.4M | 151.6M | 138.1M | 123.1M | 109.7M | 87.8M | 43.2M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $902.1M | $714.0M | $635.4M | $376.5M | $493.8M | $400.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $957.0M | $776.2M | $666.4M | $405.8M | $515.6M | $412.5M |
| Total liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $45.7M | $21.0M |
| Shareholders' equity | $852.6M | $707.4M | $617.8M | $362.5M | $469.8M | $391.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology